within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AC02_Itraconazole;

model Itraconazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.55,
    Cl = 6.961111111111111e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.01,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007,
    Tlag = 30.0,
    Vdp = 0.0184,
    k12 = 9.994444444444444e-06,
    k21 = 9.994444444444444e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Itraconazole</td></tr><tr><td>ATC code:</td><td>J02AC02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>358</td><td>mL/hr/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Itraconazole is a triazole antifungal agent used for the treatment of various fungal infections including those caused by Aspergillus, Candida, and dermatophytes. It is FDA-approved and commonly used for systemic mycoses and onychomycosis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose of 200 mg capsule under fasting conditions.</p><h4>References</h4><ol><li><p>Sánchez, CR, et al., &amp; Papich, MG (2019). Population pharmacokinetics of itraconazole solution after a single oral administration in captive lesser flamingos (Phoeniconaias minor). <i>Journal of veterinary pharmacology and therapeutics</i> 42(1) 1–6. DOI:<a href=\"https://doi.org/10.1111/jvp.12721\">10.1111/jvp.12721</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30302773/\">https://pubmed.ncbi.nlm.nih.gov/30302773</a></p></li><li><p>Willems, L, et al., &amp; de Beule, K (2001). Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. <i>Journal of clinical pharmacy and therapeutics</i> 26(3) 159–169. DOI:<a href=\"https://doi.org/10.1046/j.1365-2710.2001.00338.x\">10.1046/j.1365-2710.2001.00338.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11422598/\">https://pubmed.ncbi.nlm.nih.gov/11422598</a></p></li><li><p>Junkert, AM, et al., &amp; Pontarolo, R (2024). Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review. <i>British journal of clinical pharmacology</i> 90(2) 528–547. DOI:<a href=\"https://doi.org/10.1111/bcp.15933\">10.1111/bcp.15933</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37850318/\">https://pubmed.ncbi.nlm.nih.gov/37850318</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J02AC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Itraconazole;
